Validating bioluminescence imaging as a high-throughput, Quantitative modality for assessing tumor burden

Zain Paroo, Robert A. Bollinger, Dwaine A. Braasch, Edmond Richer, David R. Corey, Peter P. Antich, Ralph P. Mason

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

Bioluminescence imaging (BLI) is a highly sensitive tool for visualizing tumors, neoplastic development, metastatic spread, and response to therapy. Although BLI has engendered much excitement due to its apparent simplicity and ease of implementation, few rigorous studies have been presented to validate the measurements. Here, we characterize the nature of bioluminescence output from mice bearing subcutaneous luciferase-expressing tumors over a 4-week period. Following intraperitoneal or direct intratumoral administration of luciferin substrate, there was a highly dynamic kinetic profile of light emission. Although bioluminescence was subject to variability, strong correlations (r > .8, p < .001) between caliper measured tumor volumes and peak light signal, area under light signal curve and light emission at specific time points were determined. Moreover, the profile of tumor growth, as monitored with bioluminescence, closely resembled that for caliper measurements. The study shows that despite the dynamic and variable nature of bioluminescence, where appropriate experimental precautions are taken, single time point BLI may be useful for noninvasive, high-throughput, quantitative assessment of tumor burden.

Original languageEnglish (US)
Pages (from-to)117-124
Number of pages8
JournalMolecular Imaging
Volume3
Issue number2
DOIs
StatePublished - Apr 2004

Fingerprint

Bioluminescence
Tumor Burden
Tumors
Throughput
Imaging techniques
Light
Light emission
Neoplasms
Luciferases
Bearings (structural)
Growth
Kinetics
Substrates

Keywords

  • Bioluminescent imaging
  • HeLa cells
  • Luciferase
  • Luciferin
  • Noninvasive imaging

ASJC Scopus subject areas

  • Engineering(all)

Cite this

Validating bioluminescence imaging as a high-throughput, Quantitative modality for assessing tumor burden. / Paroo, Zain; Bollinger, Robert A.; Braasch, Dwaine A.; Richer, Edmond; Corey, David R.; Antich, Peter P.; Mason, Ralph P.

In: Molecular Imaging, Vol. 3, No. 2, 04.2004, p. 117-124.

Research output: Contribution to journalArticle

Paroo, Zain ; Bollinger, Robert A. ; Braasch, Dwaine A. ; Richer, Edmond ; Corey, David R. ; Antich, Peter P. ; Mason, Ralph P. / Validating bioluminescence imaging as a high-throughput, Quantitative modality for assessing tumor burden. In: Molecular Imaging. 2004 ; Vol. 3, No. 2. pp. 117-124.
@article{66b66a624e284909bcc503d41f622c93,
title = "Validating bioluminescence imaging as a high-throughput, Quantitative modality for assessing tumor burden",
abstract = "Bioluminescence imaging (BLI) is a highly sensitive tool for visualizing tumors, neoplastic development, metastatic spread, and response to therapy. Although BLI has engendered much excitement due to its apparent simplicity and ease of implementation, few rigorous studies have been presented to validate the measurements. Here, we characterize the nature of bioluminescence output from mice bearing subcutaneous luciferase-expressing tumors over a 4-week period. Following intraperitoneal or direct intratumoral administration of luciferin substrate, there was a highly dynamic kinetic profile of light emission. Although bioluminescence was subject to variability, strong correlations (r > .8, p < .001) between caliper measured tumor volumes and peak light signal, area under light signal curve and light emission at specific time points were determined. Moreover, the profile of tumor growth, as monitored with bioluminescence, closely resembled that for caliper measurements. The study shows that despite the dynamic and variable nature of bioluminescence, where appropriate experimental precautions are taken, single time point BLI may be useful for noninvasive, high-throughput, quantitative assessment of tumor burden.",
keywords = "Bioluminescent imaging, HeLa cells, Luciferase, Luciferin, Noninvasive imaging",
author = "Zain Paroo and Bollinger, {Robert A.} and Braasch, {Dwaine A.} and Edmond Richer and Corey, {David R.} and Antich, {Peter P.} and Mason, {Ralph P.}",
year = "2004",
month = "4",
doi = "10.1162/1535350041464865",
language = "English (US)",
volume = "3",
pages = "117--124",
journal = "Molecular Imaging",
issn = "1535-3508",
publisher = "Decker Publishing",
number = "2",

}

TY - JOUR

T1 - Validating bioluminescence imaging as a high-throughput, Quantitative modality for assessing tumor burden

AU - Paroo, Zain

AU - Bollinger, Robert A.

AU - Braasch, Dwaine A.

AU - Richer, Edmond

AU - Corey, David R.

AU - Antich, Peter P.

AU - Mason, Ralph P.

PY - 2004/4

Y1 - 2004/4

N2 - Bioluminescence imaging (BLI) is a highly sensitive tool for visualizing tumors, neoplastic development, metastatic spread, and response to therapy. Although BLI has engendered much excitement due to its apparent simplicity and ease of implementation, few rigorous studies have been presented to validate the measurements. Here, we characterize the nature of bioluminescence output from mice bearing subcutaneous luciferase-expressing tumors over a 4-week period. Following intraperitoneal or direct intratumoral administration of luciferin substrate, there was a highly dynamic kinetic profile of light emission. Although bioluminescence was subject to variability, strong correlations (r > .8, p < .001) between caliper measured tumor volumes and peak light signal, area under light signal curve and light emission at specific time points were determined. Moreover, the profile of tumor growth, as monitored with bioluminescence, closely resembled that for caliper measurements. The study shows that despite the dynamic and variable nature of bioluminescence, where appropriate experimental precautions are taken, single time point BLI may be useful for noninvasive, high-throughput, quantitative assessment of tumor burden.

AB - Bioluminescence imaging (BLI) is a highly sensitive tool for visualizing tumors, neoplastic development, metastatic spread, and response to therapy. Although BLI has engendered much excitement due to its apparent simplicity and ease of implementation, few rigorous studies have been presented to validate the measurements. Here, we characterize the nature of bioluminescence output from mice bearing subcutaneous luciferase-expressing tumors over a 4-week period. Following intraperitoneal or direct intratumoral administration of luciferin substrate, there was a highly dynamic kinetic profile of light emission. Although bioluminescence was subject to variability, strong correlations (r > .8, p < .001) between caliper measured tumor volumes and peak light signal, area under light signal curve and light emission at specific time points were determined. Moreover, the profile of tumor growth, as monitored with bioluminescence, closely resembled that for caliper measurements. The study shows that despite the dynamic and variable nature of bioluminescence, where appropriate experimental precautions are taken, single time point BLI may be useful for noninvasive, high-throughput, quantitative assessment of tumor burden.

KW - Bioluminescent imaging

KW - HeLa cells

KW - Luciferase

KW - Luciferin

KW - Noninvasive imaging

UR - http://www.scopus.com/inward/record.url?scp=4644234454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644234454&partnerID=8YFLogxK

U2 - 10.1162/1535350041464865

DO - 10.1162/1535350041464865

M3 - Article

C2 - 15296676

AN - SCOPUS:4644234454

VL - 3

SP - 117

EP - 124

JO - Molecular Imaging

JF - Molecular Imaging

SN - 1535-3508

IS - 2

ER -